Accounting for intensity variation in image analysis of large-scale multiplexed clinical trial datasets.

"Conflict of interest statement: DNC has participated in advisory boards for MSD and has received research funding on behalf of the TransSCOT Consortium from HalioDx for analyses independent of this study. VHK has served as an invited speaker on behalf of Indica Labs and Sharing Progress in Cancer Care (SPCC), is on an advisory board of Takeda and has received project‐based research funding from The Image Analysis Group and Roche outside of the submitted work. All other authors declare no competing interests."

"The SCOT trial was funded by the Medical Research Council (transferred to NETSCC – Efficacy and Mechanism Evaluation) (Grant Ref: G0601705), the NIHR Health Technology Assessment Programme (Grant Ref: 14/140/84), Cancer Research UK (CRUK) Core Clinical Trials Unit Glasgow Funding (Funding Ref: C6716/A9894), and the Swedish Cancer Society. The TransSCOT sample collection was funded by a CRUK Clinical Trials Awards and Advisory Committee – Sample Collection (Grant Ref: C6716/A13941). The QUASAR 2 trial was funded by an unrestricted educational grant to DJK from Roche. This study was funded by the Oxford NIHR Comprehensive Biomedical Research Centre, a CRUK Advanced Clinician Scientist Fellowship (Ref: C26642/A27963) to DNC, a CRUK award (Ref: A25142) to the CRUK Glasgow Centre and core funding to VHK by the University of Zurich. VHK acknowledges funding by the Promedica Foundation (Ref: F‐87701‐41‐01). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health."